pharmaphorum Podcast

• On CB1s as an alternative to GLP-1s, with Punit Dhillon

  CB1 inhibition is an approach that taps into the body’s natural metabolism to burn fat while preserving muscle for more sustainable weight loss. Unlike GLP-1s, which suppress appetite, CB1 inhibition activates fat-burning processes. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Punit Dhillon, CEO of Skye Bioscience, for a conversation on CB1 inhibitor antibodies in the obesity space. Dhillon discusses GLP-1 weight-loss drugs like semaglutide having taken the world by storm, despite the concerns over side effects, as well as what CB1s could mean for the obesity and weight-loss field. You can listen to episode 227 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

  --------  

  17:23

  --------

  17:23
• Digital transformation as a third lever in the affordability debate, with Alfred Olivares

  Technology and AI can help healthcare systems tackle the affordability challenge while ensuring patients still benefit from cutting-edge treatments. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Alfred Olivares, global managing partner, healthcare & medtech, at HTEC, in a conversation addressing how innovation can reach patients in a financially sustainable way. Olivares discusses digital transformation that makes care delivery smarter, faster, and more sustainable, as well as how data-driven platforms can support pharma in negotiating outcomes-based agreements with payers like the NHS. You can listen to episode 226 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

  --------  

  20:59

  --------

  20:59
• Towards a democratic era of medicine, with Simon Kohl

  There are many efforts at the moment to transform the expensive, labour intensive, and high failure rate processes of drug discovery into automated drug design. And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail, as well as the importance of democratizing research. You can listen to episode 225 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

  --------  

  19:20

  --------

  19:20
• CDMOs: Their crucial role and how to select one, with Sigma Mostafa

  A CDMO plays a crucial role in the pharmaceutical and biotechnology industries by providing comprehensive drug development and manufacturing services, enabling companies to efficiently bring new medicines to market. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sigma Mostafa, CSO at KBI BioPharma, about the role of CDMOs and the important factors companies should consider when selecting one. Mostafa sets out what a CDMO does, how they help to advance medicine into clinical and then commercial trials, and the critical role of partnership in drug development. You can listen to episode 224 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

  --------  

  9:31

  --------

  9:31
• On US drug shortages and compounding pharmacies, with Shawn Hodges

  Drug shortages are a critical issue in the US, leaving patients and healthcare providers struggling. Compounding pharmacies, however, can curb drug shortages and help lessen this growing threat to the public's health.  In a  new pharmaphorum podcast, web editor Nicole Raleigh speaks with Shawn Hodges, CEO of Revelation Pharma, a nationwide network of 503A and 503B compounding pharmacies, spanning across various locations. Hodges discusses the true state of drug shortages in the US at the moment, the essential role compounding played during COVID-19, and opportunities for policy reform. You can listen to episode 223 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

  --------  

  12:36

  --------

  12:36

More Business podcasts

Trending Business podcasts

About pharmaphorum Podcast